Hepatitis viruses constitute a major public health problem because of the morbidity and mortality associated with the acute and chronic consequences of these infections. New immunization strategies have been developed to eliminate the spread of hepatitis B virus (HBV) and hepatitis A virus (HAV) in the United States. Recommendations have also been developed for the prevention and control of hepatitis C virus (HCV) infection. Because of the high rate of asymptomatic infection with these viruses, information about the prevalence of these diseases is needed to monitor prevention efforts. By testing a nationally representative sample of the U.S. population, NHANES will provide the most reliable estimates of age-specific prevalence needed to evaluate the effectiveness of the strategies to prevent these infections. In addition, NHANES provides the means to better define the epidemiology of other hepatitis viruses. NHANES testing for markers of infection with hepatitis viruses will be used to determine secular trends in infection rates across most age and racial/ethnic groups, and will provide a national picture of the epidemiologic determinants of these infections.
All participants aged 6 years or older are eligible to be tested.
Blood specimens are processed, stored, and shipped to the Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention. Detailed specimen collection and processing instructions are discussed in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM).
Hepatitis C Antibody
Qualitative determination of the human antibody directed against hepatitis C virus (anti-HCV) in human serum or plasma is measured using direct solid-phase enzyme immunoassay with the anti-HCV screening ELISA. Positive specimens are repeated in duplicate according to the same procedure. Repeatedly positive specimens are tested supplementally using the Chiron RIBA Processor System (Chiron Corporation, Inc.).
The Chiron RIBA HCV 3.0 Strip (confirmation test)
The Chiron RIBA 3.0 Strip Immunoblot Assay (SIA; Chiron Corporation, Inc.) is an in vitro qualitative enzyme immunoassay for the detection of antibody to hepatitis C virus (anti-HCV) in human serum or plasma.
Detection of anti-HCV by SIA methodology is based upon traditional Western and dot blotting techniques, in which specific immunogens (i.e. antigenic polyproteins) encoded by the HCV genome are immobilized onto a membrane support. Visualization of anti-HCV reactivity in specimens to the individual HCV-encoded proteins is accomplished with anti-human IgG enzyme-conjugates in conjunction with a colorimetric enzyme substrate. Samples with a positive RIBA result are reported as confirmed positive for antibody to HCV. Samples with a negative RIBA result are reported as negative for antibody to HCV and those with indeterminate RIBA results are reported as indeterminate.
Hepatitis C RNA (HCV-RNA)
The COBAS AMPLICOR HCV MONITOR Test, version 2 0 (v2.0) is an in vitro nucleic acid amplification test for the quantitation of Hepatitis C Virus RNA in human serum or plasma on the COBAS AMPLICOR Analyzer.
Hepatitis C genotype
The VERSANT ® HCV Genotype 2.0 Assay (LiPA) is a line probe assay designed to identify Hepatitis C virus (HCV) genotypes 1 to 6 in human serum or EDTA plasma samples. Subtype information is available in the majority of cases.
There were no changes (from the previous 2 years of NHANES) to equipment, lab methods or lab site.
A detailed description of the laboratory methods used can be found on the NHANES website.
Read the General Documentation on Laboratory Data file for detailed data processing and editing protocols. The analytical methods are described in the Description of Laboratory Methodology section above.
The NHANES quality assurance and quality control (QA/QC) protocols meet the 1988 Clinical Laboratory Improvement Amendments mandates. Detailed quality control and quality assurance instructions are discussed in the NHANES Laboratory/Medical Technologists Procedures Manual (LPM). Read the General Documentation on Laboratory Data file for detailed QA/QC protocols. A detailed description of the quality assurance and quality control procedures can be found on the NHANES website.
The analysis of NHANES laboratory data must be conducted with the key survey design and basic demographic variables. The NHANES Household Questionnaire Data Files contain demographic data, health indicators, and other related information collected during household interviews. They also contain all survey design variables and sample weights for these age groups. The phlebotomy file includes auxiliary information such as the conditions precluding venipuncture. The household questionnaire and phlebotomy files may be linked to the laboratory data file using the unique survey participant identifier SEQN.
The age range and constraints for hepatitis testing are as follows:
Hep C-The screening hepatitis C antibody test is performed on all examinees 6 years old or older. Samples testing positive for anti-HCV by the screening EIA test were tested in the confirmatory RIBA assay for antibody to hepatitis C virus. Samples with a positive RIBA result are reported as confirmed positive for antibody to HCV. Samples with a negative RIBA result are reported as negative for antibody to HCV. Samples with an indeterminate RIBA result are reported out as such and subsequently tested for HCV RNA to attempt to confirm the infection status of the patient. Samples that tested negative by the screening EIA test were not tested by RIBA. These samples were reported as negative for antibody to HCV. Samples that tested positive or indeterminate by the HCV RNA were subsequently tested for HCV genotype.
Exam sample weights should be used for analyses. Please refer to the Analytic Guidelines for further details on the use of sample weights and other analytic issues. The Analytic Guidelines are available on the NHANES website.
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| 1 | Positive | 114 | 114 | |
| 2 | Negative | 7280 | 7394 | |
| 5 | Indeterminate | 16 | 7410 | |
| . | Missing | 722 | 8132 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| 1 | Positive | 88 | 88 | |
| 2 | Negative | 33 | 121 | |
| . | Missing | 8011 | 8132 |
| Code or Value | Value Description | Count | Cumulative | Skip to Item |
|---|---|---|---|---|
| 1 | Genotype 1a | 53 | 53 | |
| 2 | Genotype 1b | 21 | 74 | |
| 3 | Genotype 1 other than 1a/1b/or with subtype not determined | 1 | 75 | |
| 4 | Genotype 2 | 7 | 82 | |
| 5 | Genotype 3 | 5 | 87 | |
| 6 | Genotype 4 | 0 | 87 | |
| 7 | Genotype 5 | 0 | 87 | |
| 8 | Genotype 6 | 0 | 87 | |
| 9 | Genotype undetermined | 1 | 88 | |
| . | Missing | 8044 | 8132 |